Pope Leo XIV underwent surgery on Tuesday that confirmed that he has lung cancer, and doctors removed the lower lobe of his right lung, the...

Scientists have achieved a significant breakthrough in treating pancreatic cancer in mice. A triple combination therapy led to the complete...

Stage 0 cancer, or carcinoma in situ, represents the earliest detectable phase where abnormal cells are confined to their original tissue l...

Glenmark Pharmaceuticals has partnered with Hengrui Pharma, securing exclusive rights to develop and commercialize Trastuzumab Rezetecan gl...

Cipla has secured USFDA approval to market a generic version of Abraxane, paclitaxel protein-bound particles for injectable suspension (100...

Zydus Lifesciences' subsidiary partners with Zhuhai Beihai Biotech to market Beizray, a cancer drug, in the US. Zhuhai will handle manufact...

The model analyses the spatial arrangement of cells in tissue, mimicking how pathologists read slides.

Non-smokers are also susceptible to different types of lung cancer.

The EasyCheck- Breast test developed by Nashik-based molecular diagnostics company Datar Cancer Genetics, has received breakthrough designa...

The case involved one Alok Kumar Banerjee from Thaltej, who underwent treatment for adenocarcinoma of the lung from Vedanta Institute of Me...

Lung cancer is the leading cause of cancer-related deaths worldwide. Environmental risk factors, such as exposure to radon, air pollution, ...

BI and Lupin will together develop and commercialise a new drug called MEK inhibitor that will target specific cancer cells and potentially...

Shilpa Medicare has received USFDA final approval for its abbreviated new drug application.

Immunotherapy should be given as early as possible to achieve a lasting remission of the disease.

Currently, the m-cap of the company stands at Rs 1,508.61 crore.

The partnership will develop and market a generic version of Celgene's ABRAXANE which is used in treatments of breast and lung cancers.